Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ablynx : posts strong data on key drug, looks set for approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 10:40am CEST

The drug, caplacizumab, is a treatment for the rare condition acquired thrombotic thrombocytopenic purpura (aTTP) and the data revealed a 74% reduction in aTTP-related death, recurrence of aTTP or at least one major thromboembolic event during treatment with its drug.

Additionally, the proportion of individuals that experienced recurrence of aTTP during the study was found 67% lower compared to those receiving placebo treatment.

In a further bonus to the drug, the safety profile was found to be extremely strong, with no major differences found between the drug and placebo treatment. The exception being a higher level of bleed-related adverse events, 66.2% against 49.3% in placebo though they were noted to be mild or moderate in severity.

Dr Edwin Moses, CEO of Ablynx, commented: I am delighted by this outcome as it reinforces all our beliefs in the potential for caplacizumab to change the lives of patients affected by aTTP. This is a very important milestone for the company as it further validates our Nanobody platform and demonstrates our ability to discover and develop medicines that make a real difference for society. These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available.

Ablynx has already applied for marketing authorisation the EMA and plans to file with the FDA in 2018. One of the major successes for the company is that the Belgium-based biotech has taken the treatment all the way through to Phase 3 by itself and now looks set to secure the potential peak sales of $400 million exclusively. It has already announced that it plans to market the drug with its own sales force.

European biotechs have, so far, lagged behind their counterparts across the Atlantic but this success will go some way to suggesting that it is possible within Europe to develop a company able to take treatments all the way through developmental stage to potential marketing authorisation.

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
01:46p ABLYNX : 17/10/2017 ablynx announces launch of proposed global offering
01:30p ABLYNX : Announces launch of proposed global offering
10/16 ABLYNX : 16/10/2017 ablynx establishes subsidiary in the usa and appoints a gene..
10/16 ABLYNX : 16/10/2017 publication in accordance with article 14 of the belgian law..
10/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/13 ABLYNX : 13/10/2017 publication in accordance with article 14 of the belgian law..
10/13 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/06 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
More news
News from SeekingAlpha
12:29p Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
10/03 YOUR DAILY PHARMA SCOOP : Pfizer A Buy, Our Ablynx Pick Successful, VBLT, DVAX, ..
10/02 Ablynx's caplacizumab successful in late-stage study in rare blood disorder; ..
09/13 Ablynx - Catalyst Next Month, Good Midterm Buy
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 17,6x
EV / Sales 2018 19,0x
Capitalization 1 047 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,4 €
Spread / Average Target 8,1%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX63.99%1 232
INCYTE CORPORATION14.00%24 562
QUINTILES IMS HOLDINGS INC31.30%21 366
LONZA GROUP64.29%20 140
CELLTRION, INC.--.--%19 069
ALNYLAM PHARMACEUTICALS, INC.228.53%11 181